Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Should Expand Maraviroc Postmarketing Safety Plans – Cmte.

Executive Summary

Pfizer should conduct wide-ranging postmarketing studies to gather additional safety information on its CCR5 co-receptor antagonist maraviroc, FDA's Antiviral Drugs Advisory Committee recommended

You may also be interested in...



Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August

Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist

Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August

Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist

Merck Isentress advisory committee

Merck's HIV integrase inhibitor Isentress (raltegravir) will be the second potentially first-in-class HIV drug to be reviewed by FDA's Antiviral Drugs Advisory Committee in 2007. The panel will meet Sept. 5 to discuss Merck's treatment claim for use in combination with other antiretroviral agents in treatment-experienced patients with evidence of viral replication despite ongoing therapy. The panel's first meeting of 2007 was held in April to review Pfizer's CCR5 antagonist maraviroc (1"The Pink Sheet" April 30, 2007, p. 24). The committee will meet in closed session Sept. 6...

Related Content

UsernamePublicRestriction

Register

PS048309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel